eligibility_summary
Key eligibility: consent, ECOG 0–1, advanced, unresectable solid tumor limited to HR+/HER2− BC, CCA, endometrial, squamous NSCLC, TNBC, or ovarian (Japan: HR+/HER2− BC, TNBC, endometrial, ovarian), prior standard therapy exhausted, ≥1 measurable lesion (RECIST v1.1), archived tumor, adequate marrow/organ function, contraception. Exclude: prior B7H4 or TOP1i ADC, active lepto/untreated brain mets, other cancer ≤2y, ILD/pneumonitis/low O2, uncontrolled diabetes, systemic anti-infectives ≤14d.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
NCT06233942 tests: 1) BG-C9074, an antibody–drug conjugate (ADC) targeting B7-H4 (VTCN1), 2) BG-C9074 + tislelizumab, an anti–PD-1 monoclonal antibody (immune checkpoint inhibitor), 3) BG-C9074 + bevacizumab, an anti–VEGF-A monoclonal antibody (anti-angiogenic). Mechanisms: BG-C9074 binds B7-H4 on tumor cells, is internalized, and releases a cytotoxic payload to kill B7-H4–expressing cancer cells (engaging the B7 family inhibitory pathway). Tislelizumab blocks PD-1 to restore effector T-cell function and antitumor immunity. Bevacizumab neutralizes VEGF-A, inhibiting angiogenesis and potentially improving drug delivery. Targets/pathways: B7-H4–positive tumor cells, PD-1/PD-L1 axis on T cells, VEGF/VEGFR signaling in endothelial cells.